|
1.
|
Rapidis AD, Keramidas T, Panangiotopoulos
H, Andressakis D and Angelopoulos AP: Tumours of the head and neck
in the elderly: analysis of 190 patients. J Craniomaxillofac Surg.
26:153–158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
3.
|
Döbrossy L: Epidemiology of head and neck
cancer: magnitude of the problem. Cancer Metastasis Rev. 24:9–17.
2005.PubMed/NCBI
|
|
4.
|
Pai SI and Westra WH: Molecular pathology
of head and neck cancer: implications for diagnosis, prognosis, and
treatment. Annu Rev Pathol. 4:49–70. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Tejani MA, Cohen RB and Mehra R: The
contribution of cetuximab in the treatment of recurrent and/or
metastatic head and neck cancer. Biologics. 4:173–185.
2010.PubMed/NCBI
|
|
6.
|
Llewellyn CD, Johnson NW and
Warnakulasuriya KA: Risk factors for squamous cell carcinoma of the
oral cavity in young people — a comprehensive literature review.
Oral Oncol. 37:401–418. 2001.
|
|
7.
|
Llewellyn CD, Linklater K, Bell J, Johnson
NW and Warnakulasuriya KA: Squamous cell carcinoma of the oral
cavity in patients aged 45 years and under: a descriptive analysis
of 116 cases diagnosed in the South East of England from 1990 to
1997. Oral Oncol. 39:106–114. 2003.PubMed/NCBI
|
|
8.
|
Rutt AL, Hawkshaw MJ and Sataloff RT:
Laryngeal cancer in patients younger than 30 years: a review of 99
cases. Ear Nose Throat J. 89:189–192. 2010.PubMed/NCBI
|
|
9.
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Stupp R and Ruegg C: Integrin inhibitors
reaching the clinic. J Clin Oncol. 25:1637–1638. 2007.Comment on:
Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher
JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD and
Grossman SA: Phase I and correlative biology study of cilengitide
in patients with recurrent malignant glioma. J Clin Oncol 25:
1651–1657, 2007.
|
|
11.
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Hasina R and Lingen MW: Angiogenesis in
oral cancer. J Dent Educ. 65:1282–1290. 2001.
|
|
13.
|
Rüegg C, Dormond O and Foletti A:
Suppression of tumor angiogenesis through the inhibition of
integrin function and signaling in endothelial cells: which side to
target? Endothelium. 9:151–160. 2002.PubMed/NCBI
|
|
14.
|
Erovic BM, Neuchrist C, Berger U,
El-Rabadi K and Burian M: Quantitation of microvessel density in
squamous cell carcinoma of the head and neck by computer-aided
image analysis. Wien Klin Wochenschr. 117:53–57. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kurtz KA, Hoffman HT, Zimmerman MB and
Robinson RA: Perineural and vascular invasion in oral cavity
squamous carcinoma: increased incidence on re-review of slides and
by using immunohistochemical enhancement. Arch Pathol Lab Med.
29:354–359. 2005.
|
|
16.
|
Walsh JE, Lathers DM, Chi AC, Gillespie
MB, Day TA and Young MR: Mechanisms of tumor growth and metastasis
in head and neck squamous cell carcinoma. Curr Treat Options Oncol.
8:227–238. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Seiwert TY and Cohen EE: Targeting
angiogenesis in head and neck cancer. Semin Oncol. 35:274–285.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Tucker RW, Sanford KK, Handleman SL and
Jones GM: Alpha v integrin inhibitors and cancer therapy. Curr Opin
Investig Drugs. 4:722–731. 2003.PubMed/NCBI
|
|
19.
|
Cai W and Chen X: Anti-angiogenic cancer
therapy based on integrin alphavbeta3 antagonism. Anticancer Agents
Med Chem. 6:407–428. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V
and Chen X: Integrin alpha v beta 3 antagonists for anti-angiogenic
cancer treatment. Recent Pat Anticancer Drug Discov. 2:143–158.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Paolillo M, Russo MA, Serra M, Colombo L
and Schinelli S: Small molecule integrin antagonists in cancer
therapy. Mini Rev Med Chem. 9:1439–1446. 2009. View Article : Google Scholar
|
|
22.
|
Sheldrake HM and Patterson LH: Function
and antagonism of beta3 integrins in the development of cancer
therapy. Curr Cancer Drug Targets. 9:519–540. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Rathinam R and Alahari SK: Important role
of integrins in the cancer biology. Cancer Metastasis Rev.
29:223–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Dechantsreiter MA, Planker E, Mathä B,
Lohof E, Hölzemann G, Jonczyk A, Goodman SL and Kessler H:
N-Methylated cyclic RGD peptides as highly active and selective
alpha (V) beta (3) integrin antagonists. J Med Chem. 42:3033–3040.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Reardon DA, Fink KL, Mikkelsen T,
Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ,
Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ,
Wittemer SM, Nippgen J, Picard M and Nabors LB: Randomized phase II
study of cilengitide, an integrin-targeting
arginine-glycine-aspartic acid peptide, in recurrent glioblastoma
multiforme. J Clin Oncol. 26:5610–5617. 2008.with comment:
Chamberlain MC: Cilengitide: does it really represent a new
targeted therapy for recurrent glioblastoma? J Clin Oncol 27:
1921–1922, 2009.
|
|
26.
|
Reardon DA, Nabors LB, Stupp R and
Mikkelsen T: Cilengitide: an integrin-targeting
arginine-glycine-aspartic acid peptide with promising activity for
glioblastoma multiforme. Expert Opin Investig Drugs. 17:1225–1235.
2008. View Article : Google Scholar
|
|
27.
|
Raguse JD, Gath HJ, Bier J, Riess H and
Oettle H: Cilengitide (EMD 121974) arrests the growth of a heavily
pretreated highly vascularised head and neck tumour. Oral Oncol.
40:228–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hynes RO: Integrins: bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Preissner KT: Structure and biological
role of vitronectin. Annu Rev Cell Biol. 7:275–310. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Seiffert D and Smith JW: The cell adhesion
domain in plasma vitronectin is cryptic. J Biol Chem.
272:13705–13710. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Cordell JL, Falini B, Erber WN, Ghosh AK,
Abdulaziz Z, MacDonald S, Pulford KAF, Stein H and Mason DY:
Immunoenzymatic labeling of monoclonal antibodies using immune
complexes of complexes of alkaline phosphatase and monoclonal
anti-alkaline phosphatase (APAAP Complexes). J Histochem Cytochem.
32:219–229. 1984. View Article : Google Scholar
|
|
32.
|
Fabricius E-M, Langford A, Bier J, Hell B,
Wildner G-P and Blümcke S: Immunohistochemical characterization of
E48 and CD44-v6 expression in head and neck carcinomas. Cancer J.
10:325–330. 1997.
|
|
33.
|
Fabricius E-M, Guschmann M, Wildner G-P,
Langford A, Hell B and Bier J: Divergent immunohistochemical E48
and CD44-v6 antigen expression patterns between lymph node
metastases and primary squamous cell carcinomas in the head and
neck region. Cancer J. 11:153–159. 1998.
|
|
34.
|
Fabricius E-M, Guschmann M, Langford A,
Hell B and Bier J: Immunhistochemical assessment of the
tumour-associated epitopes CD44v6 and E48 in tumour-free lymph
nodes from patients with squamous cell carcinoma in the head-neck
region. Anal Cell Pathol. 20:115–129. 2000. View Article : Google Scholar
|
|
35.
|
Remmele W and Stegner HE: Vorschlag zur
einheitlichen Definition eines immunreaktiven Scores (IRS) für den
immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im
Mammagewebe. Pathologe. 8:138–140. 1987.PubMed/NCBI
|
|
36.
|
Sachs L: Angewandte Statistik - Anwendung
statistischer Methoden. 11. Auflage Springer Verlag; Berlin: pp.
8892004
|
|
37.
|
Jones J, Watt FM and Speight PM: Changes
in the expression of alpha v integrins in oral squamous cell
carcinomas. J Oral Pathol Med. 26:63–68. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Thomas GJ, Jones J and Speight PM:
Integrins and oral cancer. Oral Oncol. 33:381–388. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Vitolo D, Ciocci L, Ferrauti P, Cicerone
E, Gallo A, De Vincentiis M and Baroni CD: Alpha5 integrin
distribution and TGFbeta1 gene expression in supraglottic
carcinoma: their role in neoplastic local invasion and metastasis.
Head Neck. 22:48–56. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Thomas GJ and Speight PM: Cell adhesion
molecules and oral cancer. Crit Rev Oral Biol Med. 12:479–498.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Kramer RH, Shen X and Zhou H: Tumor cell
invasion and survival in head and neck cancer. Cancer Metastasis
Rev. 24:35–45. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Thomas GJ, Nystrom ML and Marshall JF:
Alphavbeta6 integrin in wound healing and cancer of the oral
cavity. J Oral Pathol Med. 35:1–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Reinartz J, Schäfer B, Batrla R, Klein CE
and Kramer MD: Plasmin abrogates alpha v beta 5-mediated adhesion
of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell
Res. 220:274–282. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Ziober BL, Silverman SS Jr and Kramer RH:
Adhesive mechanisms regulating invasion and metastasis in oral
cancer. Crit Rev Oral Biol Med. 12:499–510. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Lyons AJ and Jones J: Cell adhesion
molecules, the extracellular matrix and oral squamous carcinoma.
Int J Oral Maxillofac Surg. 36:671–679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Villaret AB, Schreiber A, Facchetti F,
Fisogni S, Lonardi S, Lombardi D, Cocco D, Redaelli de Zinis LO and
Nicolai P: Immunostaining patterns of CD31 and podoplanin in
previously untreated advanced oral/oropharyngeal cancer: prognostic
implications. Head Neck. 32:786–792. 2010.PubMed/NCBI
|
|
47.
|
Schnell O, Krebs B, Carlsen J, Miederer I,
Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G,
Holtmannspötter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M
and Beer AJ: Imaging of integrin {alpha} v{beta}3 expression in
patients with malignant glioma by [18F] galacto-RGD positron
emission tomography. Neuro Oncol. 11:861–870. 2009.
|
|
48.
|
Albelda SM, Mette SA, Elder DE, Stewart R,
Damjanovich L, Herlyn M and Buck CA: Integrin distribution in
malignant melanoma: association of the beta 3 subunit with tumor
progression. Cancer Res. 50:6757–6764. 1990.PubMed/NCBI
|
|
49.
|
Max R, Gerritsen RR, Nooijen PT, Goodman
SL, Sutter A, Keilholz U, Ruiter DJ and DeWaal RM:
Immunohistochemical analysis of integrin alpha vbeta3 expression on
tumor-associated vessels of human carcinomas. Int J Cancer.
71:320–324. 1997.Erratum in: Int J Cancer 72: 706–707, 1997.
|
|
50.
|
Sato T, Konishi K, Kimura H, Maeda K,
Yabushita K, Tsuji M and Miwa A: Vascular integrin beta 3 and its
relation to pulmonary metastasis of colorectal carcinoma.
Anticancer Res. 21:643–647. 2001.PubMed/NCBI
|
|
51.
|
Tang Y, Borgstrom P, Maynard J, Koziol J,
Hu Z, Garen A and Deisseroth A: Mapping of angiogenic markers for
targeting of vectors to tumor vascular endothelial cells. Cancer
Gene Ther. 14:346–353. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Beer AJ, Niemeyer M, Carlsen J, Sarbia M,
Nährig J, Watzlowik P, Wester HJ, Harbeck N and Schwaiger M:
Patterns of alphavbeta3 expression in primary and metastatic human
breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med.
49:255–259. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Gasparini G, Brooks PC, Biganzoli E,
Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R and Cheresh
DA: Vascular integrin alpha(v)beta3: a new prognostic indicator in
breast cancer. Clin Cancer Res. 4:2625–2634. 1998.PubMed/NCBI
|
|
54.
|
Vonlaufen A, Wiedle G, Borisch B, Birrer
S, Luder P and Imhof BA: Integrin alpha(v)beta(3) expression in
colon carcinoma correlates with survival. Mod Pathol. 14:1126–1132.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Schnell O, Krebs B, Wagner E, Romagna A,
Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC and
Goldbrunner RH: Expression of integrin alphavbeta3 in gliomas
correlates with tumor grade and is not restricted to tumor
vasculature. Brain Pathol. 18:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Zannetti A, Del Vecchio S, Iommelli F, Del
Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M,
Speranza A, Grieco P, Novellino E, Saviano M, Pedone C and
Salvatore M: Imaging of alphavbeta3 expression by a bifunctional
chimeric RGD peptide not cross-reacting with alphavbeta5. Clin
Cancer Res. 15:5224–5233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Monnier Y, Farmer P, Bieler G, Imaizumi N,
Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S,
Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M and Rüegg C:
CYR61 and alphaVbeta5 integrin cooperate to promote invasion and
metastasis of tumors growing in preirradiated stroma. Cancer Res.
68:7323–7331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Ricono JM, Huang M, Barnes LA, Lau SK,
Weis SM, Schlaepfer DD, Hanks SK and Cheresh DA: Specific
cross-talk between epidermal growth factor receptor and integrin
alphav-beta5 promotes carcinoma cell invasion and metastasis.
Cancer Res. 69:1383–1391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Vocca I, Franco P, Alfano D, Votta G,
Carriero MV, Estrada Y, Caputi M, Netti PA, Ossowski L and
Stoppelli MP: Inhibition of migration and invasion of carcinoma
cells by urokinase-derived antagonists of alphavbeta5 integrin
activation. Int J Cancer. 124:316–325. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Skuli N, Monferran S, Delmas C, Favre G,
Bonnet J, Toulas C and Cohen-Jonathan Moyal E:
Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for
hypoxia regulation in glioblastoma. Cancer Res. 69:3308–3316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Färber K, Synowitz M, Zahn G, Vossmeyer D,
Stragies R, van Rooijen N and Kettenmann H: An alpha5beta1 integrin
inhibitor attenuates glioma growth. Mol Cell Neurosci. 39:579–585.
2008.PubMed/NCBI
|
|
62.
|
Morozevich GE, Kozlova NI, Cheglakov IB,
Ushakova NA, Preobrazhenskaya ME and Berman AE: Implication of
alpha5-beta1 integrin in invasion of drug-resistant MCF-7/ADR
breast carcinoma cells: a role for MMP-2 collagenase. Biochemistry.
73:791–796. 2008.PubMed/NCBI
|
|
63.
|
Morozevich G, Kozlova N, Cheglakov I,
Ushakova N and Berman A: Integrin alpha5beta1 controls invasion of
human breast carcinoma cells by direct and indirect modulation of
MMP-2 collagenase activity. Cell Cycle. 8:2219–2225. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Lee MY, Huang JP, Chen YY, Aplin JD, Wu
YH, Chen CY, Chen PC and Chen CP: Angiogenesis in differentiated
placental multipotent mesenchymal stromal cells is dependent on
integrin alpha5beta1. PLoS One. 4:E69132009. View Article : Google Scholar : PubMed/NCBI
|
|
65.
|
Zahn G, Vossmeyer D, Stragies R, Wills M,
Wong CG, Löffler KU, Adamis AP and Knolle J: Preclinical evaluation
of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427
in monkey and rabbit models of choroidal neovascularization. Arch
Ophthalmol. 127:1329–1335. 2009. View Article : Google Scholar
|
|
66.
|
Morgan MR, Byron A, Humphries MJ and Bass
MD: Giving off mixed signals-distinct functions of alpha5beta1 and
alphavbeta3 integrins in regulating cell behaviour. IUBMB Life.
61:731–738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Carter A: Integrins as target: first phase
III trial launches, but questions remain. J Natl Cancer Inst.
102:675–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Wittekind Ch, Meyer HJ and Bootz F: TNM
Klassifikation Maligner Tumoren. UICC International Union Against
Cancer. 6. Aufl. Korr. Nachdruck. Kopf- und Halstumoren; pp. 19–52.
2005
|
|
69.
|
Cheresh DA and Spiro RC: Biosynthetic and
functional properties of an Arg-Gly-Asp-directed receptor involved
in human melanoma cell attachment to vitronectin, fibrinogen, and
von Willebrand factor. J Biol Chem. 262:17703–17711.
1987.PubMed/NCBI
|
|
70.
|
Weinacker A, Chen A, Agrez M, Cone RI,
Nishimura S, Wayner E, Pytela R and Sheppard D: Role of the
integrin alpha v beta 6 in cell attachment to fibronectin –
heterologous expression of intact and secreted forms of the
receptor. J Biol Chem. 269:6940–6948. 1994.
|
|
71.
|
Wayner EA, Carter WG, Piotrowicz RS and
Kunicki TJ: The function of multiple extracellular matrix receptors
in mediating cell adhesion to extracellaular matrix: preparation of
monoclonal antibodies to the fibronectin receptor that specifically
inhibit cell adhesion to fibronectin and react with platelet
glycoprotein Ic-IIa. J Cell Biol. 107:1881–1891. 1988.
|
|
72.
|
Seiffert D, Ciambrone G, Wagner NV, Binder
BR and Loskutoff DJ: The somatomedin B domain of vitronectin.
Structural requirements for the binding and stabilization of active
type 1 plasminogen activator inhibitor. J Biol Chem. 269:2659–2666.
1994.PubMed/NCBI
|
